Agensys pulls in $41M for cancer drugs

Santa Monica, Calif.-based Agensys, a biotech focused on new cancer drugs, raised $41 million in a fourth funding round. Duquesne Capital Management and JAFCO led the round, joined by Innovis Investments, Nextech Venture, Bear Stearns Health Innoventures, Alta Partners, HBM BioVentures, Lombard Odier Darier Hentsch & Cie, H&Q Life Sciences Investments, and Orbimed Associates.

IPO still on hold, Light Sciences beams up $30M

Snoqualmie, Wash.-based Light Sciences Oncology, a developer of light-activated cancer drugs, raised $30 million in a second funding round, even though it still has an IPO registration on file with the SEC. The latest funding closes out the company’s second round, which includes a $15 million investment by Fidelity Investments I wrote about here.

Reata Pharma draws $25M for cancer and inflammation drugs

Irving, Texas-based Reata Pharmaceuticals, a biotech working on new drugs to treat cancer and inflammation, raised $25 million in a fifth funding round. The round was led by existing investors, including CPMG and Novo A/S.

Aquinox Pharma pulls in $15M for cancer and inflammation

Aquinox Pharmaceuticals, a Vancouver drug developer, raised $14.5 million in a first funding round. Ventures West Capital led the round, joined by Johnson & Johnson Development Corp., Baker Brothers Investments and BC Advantage Funds.

IRX Therapeutics raises $12.5M for cancer drugs

New York’s IRX Therapeutics, a developer of drugs designed to stimulate the immune system against viruses and cancer, raised $12.5 million in a second convertible note offering. The investors were mostly private individuals, including Frank Loverro, managing director of the New York private-equity firm Kelso & Co., and other members of the firm, according to VentureWire (subscription required).

Nanopharmaceutical maker Tempo Pharma picks up $12M

Tempo Pharmaceuticals, a Cambridge, Mass., developer of new-drug formulations, raised $12.1 million in a first funding round. The company, which touts itself as a “nanopharmaceutical” maker, aims to improve the safety and effectiveness of existing drugs using engineered nanoparticles designed to home in on particular organs or tissues, then release two or more drugs in sequence. Tempo initially plans to focus on cancer.

Light Sciences Oncology, IPO on hold, raises $15M

Light Sciences Oncology, a Snoqualmie, Wash., developer of light-activated cancer drugs and delivery systems, raised $15 million in a second venture round despite having an IPO on file with the SEC, VentureWire reports (subscription required). Fidelity Investments provided the funding.

Cogent Health, maker of healthcare IT systems, raises $3M

Cogent Health Solutions, a Vancouver-based provider of computerized systems for managing cancer care, raised $3 million in its first funding round. Yaletown Venture Partners led the deal, joined by angel investors.

Cancer-drug maker Aveo raises $53M

Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors.